pretickt

Is ISRG a good stock to buy?

Intuitive Surgical, Inc. · end-of-day data as of Nov 13, 2026

Intuitive Surgical
ISRG · $154B
$443.59+0.8%
Nov 13, 2026 · close
$350$400$450SepOctNov9:3016:003 months +13.4%Nov 13 · close
▲ 4
  • PT$498.12 +12.3%
  • ConsensusBuy · 34
  • MAs3 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in76d
  • P/E53.3x
  • RSI52
  • Support-3.7%
  • Resistance+1.0%
  • Off 52w high-26.5%
  • Volume0.6x
  • Bollingerlower half
  • News0.00
  • FCF yield+2.3%
  • P/E vs own-3.9%
  • Trendsideways
  • 52w range$329–$604
  • ATR+3.3%
  • Off ATH-28.0%
▼ 3
  • P/E vs sector+65.3%
  • Insiders-$20.09M
  • MACD-2.75

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Intuitive Surgical a good stock to buy?

Intuitive Surgical is strong on 5 of the 5 questions about the business. The price is low: 53.3 times its earnings, below its 3-year median of 71.9 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage hard to copy
  3. Economics very profitable
  4. Execution delivers
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?growing

ISRG sales growth revenue growth

+17%a year, for the last 3 years

Intuitive Surgical's sales grew 17% a year for 3 years, to $10.06B in fiscal 2025.

ISRG analysts' forecast revenue estimates

+19%the sales they expect next fiscal year, on the last

Analysts expect Intuitive Surgical's sales to grow 19% to $11.93B in fiscal 2026 (24 analysts).

ISRG competitors

pretickt analysis+20%its sales in 12 months, on a year before

Intuitive Surgical's sales grew 20% in the 12 months to Sep 30, 2026, faster than West Pharmaceutical Services (+13%), ResMed (+9%), Solventum (-3%) and Becton Dickinson (-7%).

ISRG sales by business revenue by segment

60%of its sales from Instruments and Accessories

Instruments and Accessories brought Intuitive Surgical 60% of its sales in fiscal 2025; Systems 25%.

Advantage moatIs it hard to copy?hard to copy

ISRG return on capital ROIC

pretickt analysis25%earned before tax on the money invested in it

Intuitive Surgical earned 25% before tax on the capital invested in it in the 12 months to Sep 30, 2026; ResMed 34%, West Pharmaceutical Services 28%, Solventum 21% and Becton Dickinson 4%.

ISRG margin on each sale gross margin

67%left after making the product

Intuitive Surgical kept 67% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 51%.

EconomicsDoes it make good money?very profitable

ISRG margin after costs profit margin

28%of sales left after running the business

Intuitive Surgical's operating margin was 28% in the 12 months to Sep 30, 2026, against 25% in fiscal 2022.

ISRG cash generated free cash flow

$3.6Bcash left after investing, last 12 months

Intuitive Surgical generated $3.6B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

ISRG profit per share

+23%in its last fiscal year

Intuitive Surgical's earnings per share grew 23% in fiscal 2025, to $7.89.

ExecutionDoes it deliver what it promises?delivers

ISRG earnings vs estimates

8 of 8quarters above the analysts' estimate

Intuitive Surgical beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 20, 2026.

ISRG insider selling

-$64.95Msold, net, by its executives in 12 months

Intuitive Surgical's executives and directors sold a net $64.95M of shares in the 12 months to Nov 13, 2026; none bought.

ISRG number of employees

+9%more people in a year

Intuitive Surgical had 17,021 employees at the end of fiscal 2025, 9% more than a year before.

ISRG CEO pay

$21Mfor fiscal 2025, 89% of it in stock and options

Intuitive Surgical paid its CEO $21M for fiscal 2025, 89% of it in stock and options.

Fragility risksCould something break it?sturdy

ISRG financial health Altman Z-score

30.6Altman Z-score, safe above 3

Intuitive Surgical's Altman Z-score is 30.6 (Nov 13, 2026), above 3, where the safe zone starts.

ISRG quality checks Piotroski score

8 of 9checks passed

Intuitive Surgical passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.

ISRG shareholders institutional ownership

pretickt analysis
  • Vanguard8.6% ▲
  • BlackRock8.5% ▼
  • State Street4.5% ▲
2,363institutions hold it; the largest added shares

2,363 institutions hold 87% of Intuitive Surgical's shares (Jun 30, 2026); Vanguard and State Street added shares that quarter, BlackRock sold some.

ISRG in past recessions

pretickt analysis-3%its sales in the worst one

Intuitive Surgical's sales fell in 1 of the last 2 US recessions, by as much as 3% in fiscal 2020.

Price valuationIs the price reasonable?below its usual

ISRG price vs profit P/E ratio

53.3×a year's earnings

Intuitive Surgical's P/E ratio is 53.3 (Nov 13, 2026), below its 3-year median of 71.9.

ISRG price vs competitors

pretickt analysis53.3×a year's earnings, against its competitors

Investors pay 53.3 times Intuitive Surgical's earnings (Nov 13, 2026), more than for Becton Dickinson (52.7), West Pharmaceutical Services (46.7) and ResMed (21.9), less than for Solventum (99.0).

ISRG analysts' target price target

+12%to their average target

Analysts' average price target for Intuitive Surgical is $498, 12% above the Nov 13, 2026 close of $443.59.

ISRG growth priced in fair value

pretickt analysis+17%a year, for ten years, to be worth the price

At $443.59 a share, Intuitive Surgical's free cash flow must grow about 17% a year for ten years to be worth the price (Nov 13, 2026).

What is Intuitive Surgical's P/E ratio?

Intuitive Surgical's P/E ratio is 53.3 (Nov 13, 2026), below its 3-year median of 71.9. Investors pay 53.3 times Intuitive Surgical's earnings (Nov 13, 2026), more than for Becton Dickinson (52.7), West Pharmaceutical Services (46.7) and ResMed (21.9), less than for Solventum (99.0).

Who are Intuitive Surgical's biggest competitors?

pretickt compares Intuitive Surgical with Becton Dickinson, ResMed, West Pharmaceutical Services and Solventum. Intuitive Surgical's sales grew 20% in the 12 months to Sep 30, 2026, faster than West Pharmaceutical Services (+13%), ResMed (+9%), Solventum (-3%) and Becton Dickinson (-7%).

Is Intuitive Surgical profitable?

Intuitive Surgical's operating margin was 28% in the 12 months to Sep 30, 2026, against 25% in fiscal 2022. Intuitive Surgical generated $3.6B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

Are insiders selling Intuitive Surgical stock?

Intuitive Surgical's executives and directors sold a net $64.95M of shares in the 12 months to Nov 13, 2026; none bought.

How does Intuitive Surgical make money?

Instruments and Accessories brought Intuitive Surgical 60% of its sales in fiscal 2025; Systems 25%.

Who owns Intuitive Surgical stock?

2,363 institutions hold 87% of Intuitive Surgical's shares (Jun 30, 2026); Vanguard and State Street added shares that quarter, BlackRock sold some.

How many employees does Intuitive Surgical have?

Intuitive Surgical had 17,021 employees at the end of fiscal 2025, 9% more than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.